<DOC>
	<DOCNO>NCT01397201</DOCNO>
	<brief_summary>The aim study ass compare efficacy safety BI 54903 3 dos twice daily ( b.i.d . ) , fluticasone propionate hydrofluoroalkane meter dose inhaler ( HFA MDI ) dose 220 mcg b.i.d . placebo b.i.d . 8-week treatment period asthmatic patient age 12 65 year inadequately control low dose Inhaled corticosteroid ( ICS ) demonstrate decrease forced expiratory volume one second ( FEV1 ( range 10-25 % ) asthma control questionnaire ( ACQ-6 ) great equal 1.5 time randomisation</brief_summary>
	<brief_title>Study BI 54903 ( Inhaled Corticosteroid ) Administered Twice Daily Via Respimat Inhaler Patients With Asthma Inadequately Controlled Low Dose Inhaled Corticosteroid ( ICS )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : 1 . Must willing able give inform consent 2 . Male female patient age least 12 65 year 3 . All patient must history asthma diagnose physician least three month time enrolment trial accord 2009 Global Initiative Asthma ( GINA ) Guidelines . The initial diagnosis asthma must make age 40 year 4 . All patient must maintenance treatment either mediumdose inhaled corticosteroid ( ICS ) plus long acting beta agonist ( LABA ) highdose inhale corticosteroid ( ICS ) without long act beta agonist ( LABA ) , stable least six week prior Visit 1 5 . All patient must prebronchodilator forced expiratory volume one second ( FEV1 ) less 60 90 % predict normal asthma control questionnaire ( ACQ6 ) mean score less 1.5 prescreening Visit 1 6 . All patient must improvement FEV1 le 12 % baseline absolute change least 200 mL within 1530 min administration 400 mcg salbutamol/albuterol hydrofluoroalkane meter dose inhaler ( HFA MDI ) 7 . Patients must neversmokers exsmokers smoke history le 10 packyears smoke cessation least one year prior screen 8 . Patients must able use Respimat® inhaler meter dose inhaler ( MDI ) correctly 9 . Patients must able perform trialrelated procedure include technically acceptable pulmonary function test electronic peak expiratory flow ( PEF ) measurement , must able maintain record study period require protocol 10 . To enter treatment period follow additional criterion meet ( randomisation visit ) : During runin period ( clinic visit ) patient must symptomatic ( ACQ6 mean score equal great 1.5 ) show decrease morning prebronchodilator FEV1 le 10 % less equal 25 % prescreening baseline FEV1 Visit 2 . Exclusion criterion : 1 . Patients significant pulmonary disease asthma significant medical condition ( determine medical history , examination clinical investigation screen ) 2 . Patients clinically relevant , abnormal screen haematology and/or blood chemistry find 3 . Patients history upper low respiratory tract infection past four week prior prescreening Visit 1 , prescreening runin period 4 . Patients exacerbation underlie asthma eight week prior prescreening Visit 1 5 . Patients active allergic rhinitis require treatment systemic corticosteroid 6 . Any following criterion meet prescreening / runin period ( Visits 1 6 ) : clinic prebronchodilator force expiratory volume one second ( FEV1 % ) predict less 40 % , 12 puff rescue salbutamol/albuterol hydrofluoroalkane meter dose inhaler ( HFA MDI ) per day &gt; 2 consecutive day , exacerbation asthma . 7 . Patients history pneumonectomy plan undergo thoracotomy reason 8 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program six week prior first screen visit 1 9 . Patients two hospitalization asthma within previous twelve month 10 . Patients recent history myocardial infarction last twelve month know coronary heart disease require treatment 11 . Patients history hospitalisation due heart failure past twelve month 12 . Patients myocarditis unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year 13 . Patients significant alcohol drug abuse opinion investigator within past two year 14 . Patients rheumatoid arthritis systemic disease require immune system modulate treatment 15 . Patients suffer narrow angle glaucoma history glaucoma , increase intraocular pressure , and/or cataract 16 . Pregnant nursing woman 17 . Women childbearing potential use highly effective method birth control . 18 . Patients treated antiImmunoglobinEantibodies ( e.g . omalizumab , Xolair® ) immune system modulate antibody tumor necrosis factoralpha blocker within six month prior Visit 1 19 . Patients treat follow drug past four week prior Visit 1 foreseen need study : Nonselective betablockers ( topical cardioselective betablocker eye medication nonnarrow angle glaucoma allow ) , Oral systemic corticosteroid , Oral betaagonists , Changes allergen desensitisation therapy last 6 month , Immune system modulate agent methotrexate cyclosporine , Inhibitors cytochrome P450 3A4 antifungal ( e.g . ketoconazole , itraconazole ) , antibiotic ( e.g . erythromycin ) antiretroviral drug . Patients treat leukotriene modifier , chromones theophylline within two week prior Visit 1 Patients treat tiotropium within 3 week prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>